Optimizing Statin Treatment Decisions for Diabetes Patients in the Presence of Uncertain Future Adherence

Edward P. Fitts Department of Industrial & Systems Engineering, North Carolina State University, Raleigh, North Carolina 27613, USA.
Medical Decision Making (Impact Factor: 3.24). 04/2011; 32(1):154-66. DOI: 10.1177/0272989X11404076
Source: PubMed


Statins are an important part of the treatment plan for patients with type 2 diabetes. However, patients who are prescribed statins often take less than the prescribed amount or stop taking the drug altogether. This suboptimal adherence may decrease the benefit of statin initiation.
To estimate the influence of adherence on the optimal timing of statin initiation for patients with type 2 diabetes.
The authors use a Markov decision process (MDP) model to optimize the treatment decision for patients with type 2 diabetes. Their model incorporates a Markov model linking adherence to treatment effectiveness and long-term health outcomes. They determine the optimal time of statin initiation that minimizes expected costs and maximizes expected quality-adjusted life years (QALYs).
In the long run, approximately 25% of patients remain highly adherent to statins. Based on the MDP model, generic statins lower costs in men and result in a small increase in costs in women relative to no treatment. Patients are able to noticeably increase their expected QALYs by 0.5 to 2 years depending on the level of adherence.
Adherence-improving interventions can increase expected QALYs by as much as 1.5 years. Given suboptimal adherence to statins, it is optimal to delay the start time for statins; however, changing the start time alone does not lead to significant changes in costs or QALYs.

Download full-text


Available from: Jennifer Mason Lobo,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Medical decisions often involve tradeoff among competing criteria. For example, patients with third-party health insurance are primarily concerned about maximizing their quality-adjusted lifespan, since the majority of the cost burden typically falls on the third-party payer. On the other hand, third-party payers are incented to minimize total healthcare-related costs. Therefore, third-party payers must weigh the short-term cost of treatment against the long-term benefits of avoiding more costly health outcomes associated with disease progression and adverse events. The goal of the societal perspective is to achieve a reasonable balance among these competing criteria of quality-adjusted lifespan and costs. Treatment of diabetes provides a good example of the need to apply multicriteria decision-making models to treatment decisions. Chronic diseases such as diabetes are associated with high medical costs and a large number of available treatment options. In this paper, we use a Markov decision process (MDP) to show how decision-maker perspectives can influence medical treatment decisions related to cardiovascular risk management in patients with type 2 diabetes. We compare optimal treatment decisions from three different perspectives: societal, patient, and third-party payer. We further formulate an inverse MDP model to estimate the implied monetary value of a year of life, from the societal perspective, according to current U.S. treatment guidelines.
    Ibm Journal of Research and Development 09/2012; 56(5):8:1-8:12. DOI:10.1147/JRD.2012.2201849 · 0.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adherence to statins in real-world practice settings is known to be suboptimal. However, less is known about how adherence changes over time and whether changes in adherence are associated with adverse cardiovascular (CV) outcomes. To (a) characterize yearly changes in adherence among initially adherent patients taking statins for primary prevention and (b) assess the association between changes in statin adherence with subsequent risk of CV events. A 10% random sample of the IMS LifeLink Health Plan Claims Database covering the time period from July 1, 1997, to December 31, 2008, was used to identify a cohort of primary prevention statin users. Adherence was estimated in yearly segments beginning with the index statin prescription using proportion of days covered (PDC). PDC was categorized into 3 levels: PDC ≥ 0.80, 0.20 ≤ PDC less than 0.80, PDC less than 0.20. Patients were excluded if they experienced CV events or had PDC less than 0.80 in their first year of statin exposure. Descriptive statistics were used to explore proportions of the cohort in each PDC category during each year. Cox-proportional hazards models were used to estimate the 5-year CV event risk associated with yearly adherence transitions. Of the 11,126 patients beginning at the highest level of adherence (PDC ≥ 0.80) in year 1, 70% remained at this level in year 2. Of those in this level during year 2, 73% remained at this level in year 3. 828 (7.44%) experienced a CV event during their observable follow-up time. It was found that those who transitioned from the highest to the lowest level of adherence in year 2 (PDC less than 0.20) experienced 2.26 greater CV event hazard (P less than 0.0001). Adjusting for year 2 adherence, patients at the lowest level in year 3 experienced a 271% increase in CV hazard (P less than 0.0001), as compared with the highest level of adherence. This study found that patients' adherence levels tend to decline over time, and a transition to levels of adherence lower than a PDC of 80% was associated with increased risk of CV events. These results are useful in the context of targeting interventions that aim to improve patients' adherence.
    Journal of managed care pharmacy: JMCP 01/2014; 20(1):51-7. · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: By 2030, 171 million Americans are expected to have more than one chronic condition. The cohort of individuals with multiple chronic conditions (MCC) is growing and two thirds of healthcare costs for the US population are currently spent on the 20% of people who have MCC. Objectives: Recognizing the need for increased investment in MCC programs and research, Health and Human Services (HHS) developed the HHS Strategic Framework on MCC. The Agency for Healthcare Research and Quality (AHRQ) contributed to the goals of the framework by funding the MCC Research Network, comprising 45 diverse grants and representing one of the largest federal investment in MCC studies to date. Results: The initial body of research emerging from the AHRQ MCC Research Network included: co-management of commonly co-occurring conditions (including by caregivers); care for patients with low-prevalence combinations of MCC; the effect of MCC patients on provider performance metrics; guidelines for preventive services; medication management in individuals with MCC; as well as MCC-specific methodological and analytical techniques. Conclusions: The authors describe a subset of research contributions made in each topic area and make 3 recommendations for future MCC research: (1) include person-centered and person-driven measures and outcomes, (2) consider the person in the context of their relationships and community, and (3) include mental healthcare as an essential part of overall healthcare.
    Medical Care 03/2014; volume 52:s15-s22. DOI:10.1097/MLR.0000000000000095 · 3.23 Impact Factor
Show more